| Literature DB >> 24900796 |
Xiaojun Zhang1, Wen Jiang1, Swanee Jacutin-Porte1, Peter W Glunz1, Yan Zou1, Xuhong Cheng1, Alexandra H Nirschl1, Nicholas R Wurtz1, Joseph M Luettgen1, Alan R Rendina1, Gang Luo1, Timothy M Harper1, Anzhi Wei2, Rushith Anumula3, Daniel L Cheney1, Robert M Knabb2, Pancras C Wong1, Ruth R Wexler1, E Scott Priestley1.
Abstract
Inhibitors of the Tissue Factor/Factor VIIa (TF-FVIIa) complex are promising novel anticoagulants that show excellent efficacy and minimal bleeding in preclinical models. On the basis of a zwitterionic phenylglycine acylsulfonamide 1, a phenylglycine benzylamide 2 was shown to possess improved permeability and oral bioavailability. Optimization of the benzylamide, guided by X-ray crystallography, led to a potent TF-FVIIa inhibitor 18i with promising oral bioavailability, but promiscuous activity in an in vitro safety panel of receptors and enzymes. Introducing an acid on the pyrrolidine ring, guided by molecular modeling, resulted in highly potent, selective, and efficacious TF-FVIIa inhibitors with clean in vitro safety profile. The pyrrolidine acid 20 showed a moderate clearance, low volume of distribution, and a short t 1/2 in dog PK studies.Entities:
Keywords: TF-FVIIa inhibitor; aminoisoquinoline; anticoagulant; phenylglycinamide; phenylpyrrolidine; structure-based drug design
Year: 2013 PMID: 24900796 PMCID: PMC4027585 DOI: 10.1021/ml400453z
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345